Manulife's U.S. division, John Hancock Financial, has successfully completed its previously announced acquisition of New York Life's Retirement Plan Services business.
Valeant Pharmaceuticals International has completed the previously announced acquisition of Salix Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about US$3.2 billion in a move to strengthen its position on central nervous system condition treatments.
The largest health insurer in the United States, UnitedHealth, plans to spend more than US$12 billion to buy pharmacy benefits manager Catamaran Corp., one of the top healthcare stocks listed on the Toronto Stock Exchange.
Vontobel Asset Management has agreed to acquire a 60% stake in TwentyFour Asset Management LLP, an independent fixed income specialist based in London.
Canada’s Valeant Pharmaceuticals International has raised its bid to acquire Salix Pharmaceuticals for about US$11.1 billion ($14.2 billion).
Dublin-based Endo International has made an unsolicited bid to acquire Salix Pharmaceuticals for about US$11 billion.
AbbVie, which terminated its deal to purchase Shire last year, has agreed to acquire Pharmacyclics for US$21 billion.
Mercer has acquired a 9.9% stake in Benefitfocus, a U.S. provider of cloud-based benefits software solutions, for US$74.7 million.
After failing to buy Allergan, Canada's Valeant Pharmaceuticals International has agreed to purchase Salix Pharmaceuticals for US$14.5 billion.